Top priority for the IPO proceeds will be MZE829, an oral APOL1 inhibitor being tested for APOL1 kidney disease, with dosing in an ongoing phase 2 expected to begin in the coming weeks.

Though born and raised in Allentown, Pennsylvania, Lutz wields the English language like a polymath émigré—Nabokov if Nabokov ...

Morning Coffee May Protect the Heart Better Than All-Day Coffee Drinking Jan. 7, 2025 — People who drink coffee in the morning have a lower risk of dying from cardiovascular disease and a lower ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.

Today Early in the fall, experts might also see more cases of respiratory syncytial virus, Dr. Geeta Sood, assistant professor of medicine and epidemiologist at Johns Hopkins Bayview Medical Center, ...

Hospitalizations and deaths show how severe COVID-19 infections are. Wastewater and emergency room data show changes in COVID-19 spread in a community. Reported case numbers do not show all the ...

In the corner of a bustling warehouse in San Diego, Diane Hoffoss, PhD, stands surrounded by circuitry and LED lights. It's a far cry from the abstrac… ...

一个还算强大的Web思维导图。A relatively powerful web mind map.